Study of peripheral T-cell lymphoma outcomes in real-world care
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study is looking at how peripheral T-cell lymphoma (PTCL) behaves and responds to treatment in real-world settings. It includes patients diagnosed over many years to better understand the disease and improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with a peripheral T-cell lymphoma (PTCL) by a biopsy.
- Your diagnosis was made between 2010 and 2024, or you are newly diagnosed starting October 2025.
- Your main treatment and follow-up care is (or was) at one of the participating hospitals.
- You do not have NK/T-cell lymphoma or a lymphoma that starts in the skin (primary cutaneous T-cell lymphoma).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
This study compares two types of stem cell transplants (from a donor or your own cells) for people with certain T-cell lymphomas who had only a partial response to first chemotherapy. It aims to see which approach may work better.
This is an observational registry that collects real-world information about people newly diagnosed with peripheral T-cell or certain NK-cell lymphomas. It does not test a new drug, but it helps researchers understand patterns of disease and care, which can guide future studies.
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
This trial tests a combination of four chemotherapy drugs for people with a type of lymphoma called peripheral T-cell lymphoma who have not had treatment before. The goal is to see if this combination can help control the cancer.
This study looks at why lymphoma happens and what factors affect how well people do. It collects information from patients diagnosed between 2007 and 2027 to better understand the disease.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.